- Home
- PCG vs EW Comparison
PCG vs EW Comparison
Compare PCG & EW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PCG
- EW
- Stock Information
- Founded
- PCG 1905
- EW 1958
- Country
- PCG United States
- EW United States
- Employees
- PCG N/A
- EW N/A
- Industry
- PCG Power Generation
- EW Industrial Specialties
- Sector
- PCG Utilities
- EW Health Care
- Exchange
- PCG Nasdaq
- EW Nasdaq
- Market Cap
- PCG 37.8B
- EW 40.7B
- IPO Year
- PCG N/A
- EW 2000
- Fundamental
- Price
- PCG $17.87
- EW $77.98
- Analyst Decision
- PCG Buy
- EW Buy
- Analyst Count
- PCG 14
- EW 20
- Target Price
- PCG $21.25
- EW $79.60
- AVG Volume (30 Days)
- PCG 13.4M
- EW 4.7M
- Earning Date
- PCG 04-24-2025
- EW 04-23-2025
- Dividend Yield
- PCG 0.56%
- EW N/A
- EPS Growth
- PCG N/A
- EW 200.69
- EPS
- PCG 1.09
- EW 7.02
- Revenue
- PCG $24,541,000,000.00
- EW $5,522,300,000.00
- Revenue This Year
- PCG $6.16
- EW $11.68
- Revenue Next Year
- PCG $2.87
- EW $9.50
- P/E Ratio
- PCG $16.36
- EW $11.11
- Revenue Growth
- PCG 1.91
- EW 8.23
- 52 Week Low
- PCG $14.99
- EW $58.93
- 52 Week High
- PCG $21.72
- EW $95.25
- Technical
- Relative Strength Index (RSI)
- PCG 63.29
- EW 67.00
- Support Level
- PCG $16.70
- EW $73.61
- Resistance Level
- PCG $17.47
- EW $76.13
- Average True Range (ATR)
- PCG 0.39
- EW 1.47
- MACD
- PCG 0.05
- EW 0.19
- Stochastic Oscillator
- PCG 95.09
- EW 93.58
About PCG Pacific Gas & Electric Co.
PG&E is a holding company whose main subsidiary is Pacific Gas and Electric, a regulated utility operating in Central and Northern California that serves 5.3 million electricity customers and 4.6 million gas customers in 47 of the state's 58 counties. PG&E operated under bankruptcy court supervision between January 2019 and June 2020. In 2004, PG&E sold its unregulated assets as part of an earlier postbankruptcy reorganization.
About EW Edwards Lifesciences Corporation
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.